Amgen
Biotech

Amgen posts ph. 3 Sjögren’s data ahead of Novartis showdown

Amgen shared data from a phase 3 Sjögren’s disease trial that dazzled analysts, digging into the details that could shape its showdown with Novartis.
Nick Paul Taylor Nov 11, 2026 8:00am
akt health

Why scientific progress depends on knowing when to look again

Brought to you by Ipsen
a lot of scissors

Capricor, NextCure shed light on recent layoffs

Nov 11, 2026 4:48am
Advanced Analytics Help Reduce Control Animal Use While Preserving Scientific Rigor

How Virtual Control Groups Are Shaping Safety Studies

Brought to you by Charles River Laboratories
sickle cell disease

Beam’s sickle cell results signal Casgevy, Lyfgenia showdown

Nov 10, 2026 3:19pm
Counsel Health and Oura image for ACCESS model
Favicon Fierce Healthcare

Oura to acquire AI virtual care partner Counsel Health for $625M

Nov 10, 2026 3:09pm
More News

PepGen’s stock doubles as midphase DM1 data wow analysts

Nov 10, 2026 10:21am

AstraZeneca buys partner Omniose for bacterial vaccine tech

Nov 10, 2026 10:16am

Fierce Biotech Fundraising Tracker '26: Oyster, Delix & more

Nov 10, 2026 10:00am

Mirum scores again in hep D phase 3, setting up FDA run

Nov 10, 2026 10:00am